Corus Pharma is a U.S.-based biotech and specialty drug company founded in 2001. The company focuses on advancing respiratory and infectious disease treatments through innovative inhalable therapies. Their product portfolio includes Corus 1020, an inhalable form of the antibiotic aztreonam for respiratory infections in cystic fibrosis patients, and Corus 1030, an inhaled lidocaine solution for severe persistent asthma. In April 2006, Corus Pharma received a significant $25.00MVenture Round investment from Gilead Sciences. Subsequently, on October 22, 2006, Gilead Sciences acquired Corus Pharma, signaling recognition of the company's potential and innovative approach in addressing severe respiratory conditions.
Corus Pharma
Driving advancements in respiratory health with innovative inhalable treatments.
Founded 2001
Venture round
Total: $150.20M
Biotechnology, Health Care +1
General Information
Company Name
Corus Pharma
Founded Year
2001
Industries
Biotechnology, Health Care, Pharmaceutical
Funding Stage
Venture round
BounceWatch is an independent company data service, not affiliated with Corus Pharma. To contact Corus Pharma, visit coruspharma.com.
Is this your company?
Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.
Get Verified
How does Corus Pharma compare?
A PDF of Corus Pharma and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.
This takes a few seconds: we look beyond our own index too.
Meeting Corus Pharma soon?
A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample
Discover More
About Corus Pharma
Business keywords: Biotech, Specialty drugs, Respiratory health, Inhalable treatments, Cystic fibrosis, Antibiotics, Infectious diseases, Biopharmaceutical, Drug development, Therapeutics, Acquisition, Gilead Sciences, Innovative treatments, Lidocaine, Asthma
Funding Rounds & Investors (5)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Venture Round | $25.00M | 1 |
|
12 Apr 2006 |
| Series C | $65.00M | 9 |
|
13 Apr 2004 |
| Series B | $40.00M | - |
|
07 Mar 2003 |
| Grant | $1.70M | - |
|
03 Oct 2002 |
| Series A | $18.50M | - |
|
06 Jun 2001 |
Corus Pharma Alternatives & Competitors
View All Alternatives
Corus Pharma vs
Corus Pharma vs
Small molecule therapeutics R&D company focused on developing new drugs to combat antibiotic resista...
Venture round
17 employees
Biotechnology, Health Care
Corus Pharma vs
ProQR Therapeutics
The Netherlands
Advancing our proprietary Axiomer™ RNA-editing platform technology
Grant
201 employees
Biotechnology, Health Care
FAQ About Corus Pharma
Driving advancements in respiratory health with innovative inhalable treatments.
Corus Pharma was founded in 2001.
Corus Pharma operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Biotech, Specialty drugs, Respiratory health and Inhalable treatments.
Corus Pharma has completed 5 funding rounds, raising a total of $150.20M. The latest funding stage is Venture round.
Top alternatives and competitors to Corus Pharma include SolAeroMed Inc., Curza, ProQR Therapeutics, Lumobiotics GmbH, AM-Pharma. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Corus Pharma and SolAeroMed Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.
Source: BounceWatch company record for Corus Pharma, https://bouncewatch.com/company/corus-pharma, updated 12 September 2024. When citing, please name BounceWatch and link this page.
